Reports - Radiopharmaceuticals Market
HealthcareRadiopharmaceuticals Market
Radiopharmaceuticals Market Valuation and Future Projections to 2035 by Type (Diagnostic Nuclear Medicine, SPECT Radiopharmaceuticals, Technetium-99m, Thallium-201, Gallium-67, Iodine-123, Other, PET Radiopharmaceuticals, F-18, RU-82, Others, Therapeutic Nuclear Medicine, Alpha Emitters, Ra-223, Brachytherapy Isotopes, Intoiodine-125, Palladium-103, Cesium-131, Iridium-192, Other brachytherapy isotopes, Beta Emitters, Intoiodine-131, Yttrium-90, Samarium-153, Lutetium-177, Rhenium-186, Other beta emitters) by Application (Diagnostic Applications, SPECT Applications, Cardiology, Bone Scans, Thyroid Applications, Pulmonary Scans, Other SPECT Applications, PET applications, Oncology, Cardiology, Neurology, Other PET applications, Therapeutic Applications, Thyroid Indications, Bone Metastasis, Lymphoma, Endocrine Tumors, Other Indications) by Procedural Volume Assessment (Diagnostic Procedures, Therapeutic Procedures, Source) by Source (Nuclear Reactors, Cyclotrons) by End User (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Cancer Research Institutes, Others) by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Industry Leaders Trust Us For Actionable Intelligence
Table of Contents
Chapter 1 Executive Dashboard
1. Strategic Imperatives
Chapter 2 Premium Insights
1. Top 3 Trends to Watch
2. Demand and Supply Trends
3. Top 3 Strategies Followed by Major Players
4. Top 3 Predictions by Vantage Market Research
5. Top Investment Pockets
6. Insights from Primary Respondents
Chapter 3 Global Radiopharmaceuticals Market - Segment Analysis
1. Overview
2. Global Radiopharmaceuticals Market, 2021 - 2035 (USD Million)
3. Global Radiopharmaceuticals Market - by Type
3.1. By Diagnostic Nuclear Medicine
3.2. By SPECT Radiopharmaceuticals
3.3. By Technetium-99m
3.4. By Thallium-201
3.5. By Gallium-67
3.6. By Iodine-123
3.7. By Other
3.8. By PET Radiopharmaceuticals
3.9. By F-18
3.10. By RU-82
3.11. By Others
3.12. By Therapeutic Nuclear Medicine
3.13. By Alpha Emitters
3.14. By Ra-223
3.15. By Brachytherapy Isotopes
3.16. By Intoiodine-125
3.17. By Palladium-103
3.18. By Cesium-131
3.19. By Iridium-192
3.20. By Other brachytherapy isotopes
3.21. By Beta Emitters
3.22. By Intoiodine-131
3.23. By Yttrium-90
3.24. By Samarium-153
3.25. By Lutetium-177
3.26. By Rhenium-186
3.27. By Other beta emitters
4. Global Radiopharmaceuticals Market - by Application
4.1. By Diagnostic Applications
4.2. By SPECT Applications
4.3. By Cardiology
4.4. By Bone Scans
4.5. By Thyroid Applications
4.6. By Pulmonary Scans
4.7. By Other SPECT Applications
4.8. By PET applications
4.9. By Oncology
4.10. By Cardiology
4.11. By Neurology
4.12. By Other PET applications
4.13. By Therapeutic Applications
4.14. By Thyroid Indications
4.15. By Bone Metastasis
4.16. By Lymphoma
4.17. By Endocrine Tumors
4.18. By Other Indications
5. Global Radiopharmaceuticals Market - by Procedural Volume Assessment
5.1. By Diagnostic Procedures
5.2. By Therapeutic Procedures
5.3. By Source
6. Global Radiopharmaceuticals Market - by Source
6.1. By Nuclear Reactors
6.2. By Cyclotrons
7. Global Radiopharmaceuticals Market - by End User
7.1. By Hospitals
7.2. By Ambulatory Surgical Centers
7.3. By Diagnostic Centers
7.4. By Cancer Research Institutes
7.5. By Others
8. Global Radiopharmaceuticals Market - by region
8.1. North America
8.2. Europe
8.3. Asia Pacific
8.4. Latin America
8.5. Middle East & Africa
9. Market comparative analysis
Chapter 4 North America Radiopharmaceuticals Market - Segment Analysis
1. Overview
2. North America Radiopharmaceuticals Market, 2021 - 2035 (USD Million)
3. North America Radiopharmaceuticals Market - by Type
3.1. By Diagnostic Nuclear Medicine
3.2. By SPECT Radiopharmaceuticals
3.3. By Technetium-99m
3.4. By Thallium-201
3.5. By Gallium-67
3.6. By Iodine-123
3.7. By Other
3.8. By PET Radiopharmaceuticals
3.9. By F-18
3.10. By RU-82
3.11. By Others
3.12. By Therapeutic Nuclear Medicine
3.13. By Alpha Emitters
3.14. By Ra-223
3.15. By Brachytherapy Isotopes
3.16. By Intoiodine-125
3.17. By Palladium-103
3.18. By Cesium-131
3.19. By Iridium-192
3.20. By Other brachytherapy isotopes
3.21. By Beta Emitters
3.22. By Intoiodine-131
3.23. By Yttrium-90
3.24. By Samarium-153
3.25. By Lutetium-177
3.26. By Rhenium-186
3.27. By Other beta emitters
4. North America Radiopharmaceuticals Market - by Application
4.1. By Diagnostic Applications
4.2. By SPECT Applications
4.3. By Cardiology
4.4. By Bone Scans
4.5. By Thyroid Applications
4.6. By Pulmonary Scans
4.7. By Other SPECT Applications
4.8. By PET applications
4.9. By Oncology
4.10. By Cardiology
4.11. By Neurology
4.12. By Other PET applications
4.13. By Therapeutic Applications
4.14. By Thyroid Indications
4.15. By Bone Metastasis
4.16. By Lymphoma
4.17. By Endocrine Tumors
4.18. By Other Indications
5. North America Radiopharmaceuticals Market - by Procedural Volume Assessment
5.1. By Diagnostic Procedures
5.2. By Therapeutic Procedures
5.3. By Source
6. North America Radiopharmaceuticals Market - by Source
6.1. By Nuclear Reactors
6.2. By Cyclotrons
7. North America Radiopharmaceuticals Market - by End User
7.1. By Hospitals
7.2. By Ambulatory Surgical Centers
7.3. By Diagnostic Centers
7.4. By Cancer Research Institutes
7.5. By Others
Chapter 5 Europe Radiopharmaceuticals Market - Segment Analysis
1. Overview
2. Europe Radiopharmaceuticals Market, 2021 - 2035 (USD Million)
3. Europe Radiopharmaceuticals Market - by Type
3.1. By Diagnostic Nuclear Medicine
3.2. By SPECT Radiopharmaceuticals
3.3. By Technetium-99m
3.4. By Thallium-201
3.5. By Gallium-67
3.6. By Iodine-123
3.7. By Other
3.8. By PET Radiopharmaceuticals
3.9. By F-18
3.10. By RU-82
3.11. By Others
3.12. By Therapeutic Nuclear Medicine
3.13. By Alpha Emitters
3.14. By Ra-223
3.15. By Brachytherapy Isotopes
3.16. By Intoiodine-125
3.17. By Palladium-103
3.18. By Cesium-131
3.19. By Iridium-192
3.20. By Other brachytherapy isotopes
3.21. By Beta Emitters
3.22. By Intoiodine-131
3.23. By Yttrium-90
3.24. By Samarium-153
3.25. By Lutetium-177
3.26. By Rhenium-186
3.27. By Other beta emitters
4. Europe Radiopharmaceuticals Market - by Application
4.1. By Diagnostic Applications
4.2. By SPECT Applications
4.3. By Cardiology
4.4. By Bone Scans
4.5. By Thyroid Applications
4.6. By Pulmonary Scans
4.7. By Other SPECT Applications
4.8. By PET applications
4.9. By Oncology
4.10. By Cardiology
4.11. By Neurology
4.12. By Other PET applications
4.13. By Therapeutic Applications
4.14. By Thyroid Indications
4.15. By Bone Metastasis
4.16. By Lymphoma
4.17. By Endocrine Tumors
4.18. By Other Indications
5. Europe Radiopharmaceuticals Market - by Procedural Volume Assessment
5.1. By Diagnostic Procedures
5.2. By Therapeutic Procedures
5.3. By Source
6. Europe Radiopharmaceuticals Market - by Source
6.1. By Nuclear Reactors
6.2. By Cyclotrons
7. Europe Radiopharmaceuticals Market - by End User
7.1. By Hospitals
7.2. By Ambulatory Surgical Centers
7.3. By Diagnostic Centers
7.4. By Cancer Research Institutes
7.5. By Others
Chapter 6 Asia Pacific Radiopharmaceuticals Market - Segment Analysis
1. Overview
2. Asia Pacific Radiopharmaceuticals Market, 2021 - 2035 (USD Million)
3. Asia Pacific Radiopharmaceuticals Market - by Type
3.1. By Diagnostic Nuclear Medicine
3.2. By SPECT Radiopharmaceuticals
3.3. By Technetium-99m
3.4. By Thallium-201
3.5. By Gallium-67
3.6. By Iodine-123
3.7. By Other
3.8. By PET Radiopharmaceuticals
3.9. By F-18
3.10. By RU-82
3.11. By Others
3.12. By Therapeutic Nuclear Medicine
3.13. By Alpha Emitters
3.14. By Ra-223
3.15. By Brachytherapy Isotopes
3.16. By Intoiodine-125
3.17. By Palladium-103
3.18. By Cesium-131
3.19. By Iridium-192
3.20. By Other brachytherapy isotopes
3.21. By Beta Emitters
3.22. By Intoiodine-131
3.23. By Yttrium-90
3.24. By Samarium-153
3.25. By Lutetium-177
3.26. By Rhenium-186
3.27. By Other beta emitters
4. Asia Pacific Radiopharmaceuticals Market - by Application
4.1. By Diagnostic Applications
4.2. By SPECT Applications
4.3. By Cardiology
4.4. By Bone Scans
4.5. By Thyroid Applications
4.6. By Pulmonary Scans
4.7. By Other SPECT Applications
4.8. By PET applications
4.9. By Oncology
4.10. By Cardiology
4.11. By Neurology
4.12. By Other PET applications
4.13. By Therapeutic Applications
4.14. By Thyroid Indications
4.15. By Bone Metastasis
4.16. By Lymphoma
4.17. By Endocrine Tumors
4.18. By Other Indications
5. Asia Pacific Radiopharmaceuticals Market - by Procedural Volume Assessment
5.1. By Diagnostic Procedures
5.2. By Therapeutic Procedures
5.3. By Source
6. Asia Pacific Radiopharmaceuticals Market - by Source
6.1. By Nuclear Reactors
6.2. By Cyclotrons
7. Asia Pacific Radiopharmaceuticals Market - by End User
7.1. By Hospitals
7.2. By Ambulatory Surgical Centers
7.3. By Diagnostic Centers
7.4. By Cancer Research Institutes
7.5. By Others
Chapter 7 Latin America Radiopharmaceuticals Market - Segment Analysis
1. Overview
2. Latin America Radiopharmaceuticals Market, 2021 - 2035 (USD Million)
3. Latin America Radiopharmaceuticals Market - by Type
3.1. By Diagnostic Nuclear Medicine
3.2. By SPECT Radiopharmaceuticals
3.3. By Technetium-99m
3.4. By Thallium-201
3.5. By Gallium-67
3.6. By Iodine-123
3.7. By Other
3.8. By PET Radiopharmaceuticals
3.9. By F-18
3.10. By RU-82
3.11. By Others
3.12. By Therapeutic Nuclear Medicine
3.13. By Alpha Emitters
3.14. By Ra-223
3.15. By Brachytherapy Isotopes
3.16. By Intoiodine-125
3.17. By Palladium-103
3.18. By Cesium-131
3.19. By Iridium-192
3.20. By Other brachytherapy isotopes
3.21. By Beta Emitters
3.22. By Intoiodine-131
3.23. By Yttrium-90
3.24. By Samarium-153
3.25. By Lutetium-177
3.26. By Rhenium-186
3.27. By Other beta emitters
4. Latin America Radiopharmaceuticals Market - by Application
4.1. By Diagnostic Applications
4.2. By SPECT Applications
4.3. By Cardiology
4.4. By Bone Scans
4.5. By Thyroid Applications
4.6. By Pulmonary Scans
4.7. By Other SPECT Applications
4.8. By PET applications
4.9. By Oncology
4.10. By Cardiology
4.11. By Neurology
4.12. By Other PET applications
4.13. By Therapeutic Applications
4.14. By Thyroid Indications
4.15. By Bone Metastasis
4.16. By Lymphoma
4.17. By Endocrine Tumors
4.18. By Other Indications
5. Latin America Radiopharmaceuticals Market - by Procedural Volume Assessment
5.1. By Diagnostic Procedures
5.2. By Therapeutic Procedures
5.3. By Source
6. Latin America Radiopharmaceuticals Market - by Source
6.1. By Nuclear Reactors
6.2. By Cyclotrons
7. Latin America Radiopharmaceuticals Market - by End User
7.1. By Hospitals
7.2. By Ambulatory Surgical Centers
7.3. By Diagnostic Centers
7.4. By Cancer Research Institutes
7.5. By Others
Chapter 8 Middle East & Africa Radiopharmaceuticals Market - Segment Analysis
1. Overview
2. Middle East & Africa Radiopharmaceuticals Market, 2021 - 2035 (USD Million)
3. Middle East & Africa Radiopharmaceuticals Market - by Type
3.1. By Diagnostic Nuclear Medicine
3.2. By SPECT Radiopharmaceuticals
3.3. By Technetium-99m
3.4. By Thallium-201
3.5. By Gallium-67
3.6. By Iodine-123
3.7. By Other
3.8. By PET Radiopharmaceuticals
3.9. By F-18
3.10. By RU-82
3.11. By Others
3.12. By Therapeutic Nuclear Medicine
3.13. By Alpha Emitters
3.14. By Ra-223
3.15. By Brachytherapy Isotopes
3.16. By Intoiodine-125
3.17. By Palladium-103
3.18. By Cesium-131
3.19. By Iridium-192
3.20. By Other brachytherapy isotopes
3.21. By Beta Emitters
3.22. By Intoiodine-131
3.23. By Yttrium-90
3.24. By Samarium-153
3.25. By Lutetium-177
3.26. By Rhenium-186
3.27. By Other beta emitters
4. Middle East & Africa Radiopharmaceuticals Market - by Application
4.1. By Diagnostic Applications
4.2. By SPECT Applications
4.3. By Cardiology
4.4. By Bone Scans
4.5. By Thyroid Applications
4.6. By Pulmonary Scans
4.7. By Other SPECT Applications
4.8. By PET applications
4.9. By Oncology
4.10. By Cardiology
4.11. By Neurology
4.12. By Other PET applications
4.13. By Therapeutic Applications
4.14. By Thyroid Indications
4.15. By Bone Metastasis
4.16. By Lymphoma
4.17. By Endocrine Tumors
4.18. By Other Indications
5. Middle East & Africa Radiopharmaceuticals Market - by Procedural Volume Assessment
5.1. By Diagnostic Procedures
5.2. By Therapeutic Procedures
5.3. By Source
6. Middle East & Africa Radiopharmaceuticals Market - by Source
6.1. By Nuclear Reactors
6.2. By Cyclotrons
7. Middle East & Africa Radiopharmaceuticals Market - by End User
7.1. By Hospitals
7.2. By Ambulatory Surgical Centers
7.3. By Diagnostic Centers
7.4. By Cancer Research Institutes
7.5. By Others
Chapter 9 Key Market Dynamics
1. Introduction
2. Market Drivers
3. Market Restraints
4. Market Opportunities
5. Porter's Five Forces Analysis
6. PEST Analysis
7. Regulatory Landscape
8. Technology Landscape
9. Regional Market Trends
Chapter 10 COVID 19 Impact Analysis
1. Key strategies undertaken by companies to tackle COVID-19
2. Short term dynamics
3. Long term dynamics
Chapter 11 Marketing Strategy Analysis
1. Marketing Channel
2. Direct Marketing
3. Indirect Marketing
4. Marketing Channel Development Trends
Chapter 12 Competitive Landscape
1. Competition Matrix - 2021
2. Company Market Share Analysis - 2021
3. Key Company Activities, 2018 - 2021
4. Strategic Developments - Heat Map Analysis
5. Company Offering Evaluation
6. Company Regional Presence Evaluation
Chapter 13 Company Profiles
1. Cardinal Health (U.S.)
2. GE Healthcare (U.S.)
3. Lantheus Medical Imaging (U.S.)
4. Bayer AG (Germany)
5. Bracco Imaging (Italy)
6. Nordion (Canada)
7. Advanced Accelerator Applications (France)
8. NTP Radioisotopes (South Africa)
9. NorthStar Medical Radioisotopes (U.S.)
10. Eckert & Ziegler (Germany)
11. Braun Melsungen AG (Germany)
12. Smith+Nephew (Germany)
13. Zimmer Biomet (U.S.)
14. Hanger Inc. (U.S.) and Otto Bock Healthcare GmBH (Germany)
Chapter 14 Key Primary Respondents - VERBATIM
Chapter 15 Discussion Guide
Chapter 16 Customization Offered
Chapter 17 Annexure
Chapter 18 List of Figures
Chapter 19 List of Tables
Chapter 20 List of Abbreviations
FAQ‘s
Related Reports
Contact
Toll Free Number+1 (877) 462-2282
© 2025 Vantage Market Research. All right reserved
Secured By